Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

  • Etude concernée: IFCT-1703
  • Auteurs / Authors: Mazieres J, Lafitte C, Ricordel C, Greillier L, Negre E, Zalcman G, Domblides C, Madelaine J, Bennouna J, Mascaux C, Moro-Sibilot D, Pinquie F, Cortot AB, Otto J, Cadranel J, Langlais A, Morin F, Westeel V, Besse B.
  • Journal / Conference: Journal of Clinical Oncology
  • Année / Year: 2022
  • PMID: 35073148
  • Lien vers la publication: https://pubmed.ncbi.nlm.nih.gov/35073148/